Comparison
Why is BriaCell Therapeutics Corp. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-230.46%
EBIT to Interest (avg)
-18.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.42%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.81
EV to EBIT
-0.41
EV to EBITDA
-0.41
EV to Capital Employed
-13.87
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-200.30%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Technical Movement
4What is working for the Company
NET PROFIT(HY)
Higher at CAD -19.04 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
-6What is not working for the Company
INTEREST(9M)
At CAD 0.05 MM has Grown at inf%
ROCE(HY)
Lowest at -608.22%
Here's what is working for BriaCell Therapeutics Corp.
Net Profit
Higher at CAD -19.04 MM
than preceding 12 month period ended Apr 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CAD MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for BriaCell Therapeutics Corp.
Interest
At CAD 0.05 MM has Grown at inf%
over previous Semi-Annual periodMOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (CAD MM)






